These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 17602079

  • 1. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.
    Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, Cantor A, Bepler G.
    J Clin Oncol; 2007 Jul 01; 25(19):2741-6. PubMed ID: 17602079
    [Abstract] [Full Text] [Related]

  • 2. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A, Sørensen JB.
    Lung Cancer; 2009 May 01; 64(2):131-9. PubMed ID: 18804893
    [Abstract] [Full Text] [Related]

  • 3. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
    Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G, Muñoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D, Rosell R.
    J Clin Oncol; 2007 Jul 01; 25(19):2747-54. PubMed ID: 17602080
    [Abstract] [Full Text] [Related]

  • 4. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.
    Lung Cancer; 2009 Jun 01; 64(3):326-33. PubMed ID: 18977553
    [Abstract] [Full Text] [Related]

  • 5. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C, Ren S, Zhou S, Zhang L, Su C, Zhang Z, Deng Q, Zhang J.
    Jpn J Clin Oncol; 2010 Oct 01; 40(10):954-60. PubMed ID: 20462983
    [Abstract] [Full Text] [Related]

  • 6. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.
    Felip E, Rosell R.
    Expert Rev Mol Diagn; 2007 May 01; 7(3):261-8. PubMed ID: 17489733
    [Abstract] [Full Text] [Related]

  • 7. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP, Liu BR, Shi MQ, Liu XZ, Hu WJ, Zou ZY, Wei J.
    Zhonghua Zhong Liu Za Zhi; 2009 Jan 01; 31(1):33-7. PubMed ID: 19538866
    [Abstract] [Full Text] [Related]

  • 8. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F, Lu C, Zuhong L, Hongyan C, YuanDong C, Jiazhong J, Yingfeng Z.
    Lung Cancer; 2009 Aug 01; 65(2):230-6. PubMed ID: 19157633
    [Abstract] [Full Text] [Related]

  • 9. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L, Christiani DC.
    Clin Cancer Res; 2004 Aug 01; 10(15):4939-43. PubMed ID: 15297394
    [Abstract] [Full Text] [Related]

  • 10. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F, Sun X, Sun N, Qin S, Cheng H, Feng J, Chen B, Cheng L, Lu Z, Ji J, Zhou Y.
    Am J Clin Oncol; 2010 Oct 01; 33(5):489-94. PubMed ID: 20351547
    [Abstract] [Full Text] [Related]

  • 11. Can we customize chemotherapy? Individualizing cytotoxic regimens in advanced non-small-cell lung cancer.
    Rosell R, Manegold C, Moran T, Garrido P, Blanco R, Lianes P, Stahel R, Trigo JM, Wei J, Taron M.
    Clin Lung Cancer; 2008 Mar 01; 9 Suppl 2():S76-82. PubMed ID: 21885003
    [Abstract] [Full Text] [Related]

  • 12. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
    Olaussen KA, Mountzios G, Soria JC.
    Curr Opin Pulm Med; 2007 Jul 01; 13(4):284-9. PubMed ID: 17534174
    [Abstract] [Full Text] [Related]

  • 13. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
    Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, Kim YC, Hwang TS.
    Lung Cancer; 2004 Jun 01; 44(3):311-6. PubMed ID: 15140544
    [Abstract] [Full Text] [Related]

  • 14. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.
    Lee KH, Min HS, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Kim YT, Kim TY, Heo DS, Bang YJ, Sung SW, Kim JH.
    Lung Cancer; 2008 Jun 01; 60(3):401-7. PubMed ID: 18036700
    [Abstract] [Full Text] [Related]

  • 15. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy.
    Wachters FM, Wong LS, Timens W, Kampinga HH, Groen HJ.
    Lung Cancer; 2005 Nov 01; 50(2):211-9. PubMed ID: 16169122
    [Abstract] [Full Text] [Related]

  • 16. Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype.
    Tseden-Ish M, Choi YD, Cho HJ, Ban HJ, Oh IJ, Kim KS, Song SY, Na KJ, Ahn SJ, Choi S, Kim YC.
    Respirology; 2012 Jan 01; 17(1):127-33. PubMed ID: 21899657
    [Abstract] [Full Text] [Related]

  • 17. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.
    Simon GR, Schell MJ, Begum M, Kim J, Chiappori A, Haura E, Antonia S, Bepler G.
    Cancer; 2012 May 01; 118(9):2525-31. PubMed ID: 22028294
    [Abstract] [Full Text] [Related]

  • 18. Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer.
    Ikeda S, Takabe K, Suzuki K.
    Pathol Int; 2009 Dec 01; 59(12):863-7. PubMed ID: 20021611
    [Abstract] [Full Text] [Related]

  • 19. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis.
    Yu D, Zhang X, Liu J, Yuan P, Tan W, Guo Y, Sun T, Zhao D, Yang M, Liu J, Xu B, Lin D.
    Clin Cancer Res; 2008 May 01; 14(9):2878-86. PubMed ID: 18451256
    [Abstract] [Full Text] [Related]

  • 20. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
    Zhang GB, Chen J, Wang LR, Li J, Li MW, Xu N, Wang Y, Shentu JZ.
    Cancer Chemother Pharmacol; 2012 May 01; 69(5):1277-87. PubMed ID: 22302408
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.